Clinical Trial Update: Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC [Phase 1]

View source ↗

Summary

Phase I trial assessing ZD4054 (Zibotentan) in combination with docetaxel for metastatic castration-resistant prostate cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ZD4054 (zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED